- Home
- CMBM vs ABP Comparison
CMBM vs ABP Comparison
Compare CMBM & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- ABP
- Stock Information
- Founded
- CMBM 2011
- ABP 2004
- Country
- CMBM United States
- ABP United States
- Employees
- CMBM N/A
- ABP N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- ABP Health Care
- Exchange
- CMBM Nasdaq
- ABP Nasdaq
- Market Cap
- CMBM 17.7M
- ABP 15.2M
- IPO Year
- CMBM 2019
- ABP N/A
- Fundamental
- Price
- CMBM $2.28
- ABP $5.59
- Analyst Decision
- CMBM Buy
- ABP Hold
- Analyst Count
- CMBM 1
- ABP 1
- Target Price
- CMBM $3.00
- ABP N/A
- AVG Volume (30 Days)
- CMBM 43.3M
- ABP 301.7K
- Earning Date
- CMBM 11-06-2025
- ABP 11-13-2025
- Dividend Yield
- CMBM N/A
- ABP N/A
- EPS Growth
- CMBM N/A
- ABP N/A
- EPS
- CMBM N/A
- ABP N/A
- Revenue
- CMBM $172,215,000.00
- ABP $183,000.00
- Revenue This Year
- CMBM N/A
- ABP N/A
- Revenue Next Year
- CMBM $18.01
- ABP N/A
- P/E Ratio
- CMBM N/A
- ABP N/A
- Revenue Growth
- CMBM N/A
- ABP 154.17
- 52 Week Low
- CMBM $0.23
- ABP $4.55
- 52 Week High
- CMBM $6.80
- ABP $335.70
- Technical
- Relative Strength Index (RSI)
- CMBM 55.93
- ABP 98.04
- Support Level
- CMBM $2.04
- ABP $5.25
- Resistance Level
- CMBM $2.92
- ABP $5.96
- Average True Range (ATR)
- CMBM 0.86
- ABP 0.29
- MACD
- CMBM 0.04
- ABP 0.53
- Stochastic Oscillator
- CMBM 27.18
- ABP 89.68
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.